MARKET

MACK

MACK

Merrimack Pharma
NASDAQ
3.580
+0.020
+0.56%
Closed 16:00 10/05 EDT
OPEN
3.520
PREV CLOSE
3.560
HIGH
3.660
LOW
3.520
VOLUME
2.88K
TURNOVER
8.92K
52 WEEK HIGH
7.41
52 WEEK LOW
3.520
MARKET CAP
48.01M
P/E (TTM)
-29.8085
1D
5D
1M
3M
1Y
5Y
Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 08/16 12:11
BRIEF-Point72 Asset Management Reports 6.7% Passive Stake In Merrimack Pharmaceuticals
BRIEF-Point72 Asset Management Reports 6.7% Passive Stake In Merrimack Pharmaceuticals
Reuters · 08/04 22:09
BRIEF-Merrimack Reports Q2 Loss Per Share Of $0.04
BRIEF-Merrimack Reports Q2 Loss Per Share Of $0.04
Reuters · 08/04 21:56
Merrimack Pharmaceuticals GAAP EPS of -$0.04
Merrimack Pharmaceuticals press release (<spa...
Seekingalpha · 08/04 21:12
Merrimack Reports Second Quarter 2022 Financial Results
CAMBRIDGE, Mass., August 04, 2022--Merrimack Reports Second Quarter 2022 Financial Results
Business Wire · 08/04 21:00
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Benzinga · 08/03 22:24
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Benzinga · 08/03 18:08
Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure
Merrimack Pharmaceuticals Inc's (NASDAQ: MACK) partner announced that Ipsen SA (OTC: IPSEY) reported a primary analysis of the results of the Phase 3 trial of Onivyde (irinotecan liposomal injection)for second-line small cell lung cancer (SCLC). The study ...
Benzinga · 08/03 15:49
More
About MACK
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is entitled to receive contingent payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Its payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of ONIVYDE for certain additional clinical indications. ONIVYDE is approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.

Webull offers kinds of Merrimack Pharmaceuticals Inc stock information, including NASDAQ:MACK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MACK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MACK stock methods without spending real money on the virtual paper trading platform.